NCT06462456

Brief Summary

The purpose of this study is to assess long term performance and safety of verofilcon A soft contact lenses in a real-world setting in a population of 7 years or older having at least 1 year of verofilcon A (sphere or toric) contact lens wear in a daily wear and daily disposable modality.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2024

Shorter than P25 for all trials

Geographic Reach
1 country

12 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 17, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

August 30, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 11, 2025

Completed
Last Updated

July 20, 2025

Status Verified

July 1, 2025

Enrollment Period

6 months

First QC Date

June 12, 2024

Last Update Submit

July 17, 2025

Conditions

Keywords

MyopiaHyperopiaAstigmatism

Outcome Measures

Primary Outcomes (4)

  • Distance Visual Acuity with Study Lenses at Baseline

    Visual acuity (VA) assessed per the investigator's standard of care with study lenses in place.

    Baseline

  • Distance Visual Acuity with Study Lenses at Year 1 Follow-Up

    Visual acuity (VA) assessed per the investigator's standard of care with study lenses in place.

    Year 1

  • Incidence of Corneal Infiltrative Events

    A corneal infiltrate is a single or group of inflammatory cells in the normally clear cornea.

    Up to Year 1

  • Incidence of Microbial Keratitis

    Microbial keratitis is a sight-threatening infection of the cornea.

    Up to Year 1

Study Arms (2)

PRECISION1 Sphere

Verofilcon A spherical soft contact lenses worn in both eyes in a real-world setting

Device: Verofilcon A spherical soft contact lenses

PRECISION1 Toric

Verofilcon A toric soft contact lenses worn in both eyes in a real-world setting

Device: Verofilcon A toric soft contact lenses

Interventions

Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)

Also known as: PRECISION1™
PRECISION1 Sphere

Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism

Also known as: PRECISION1™ for Astigmatism
PRECISION1 Toric

Eligibility Criteria

Age7 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects will be recruited from clinical sites located in the United States.

You may qualify if:

  • Subject (or subject's legal representative) is able to understand and sign an informed consent/assent form approved by an Institutional Review Board (IRB), unless appropriate consent waiver for the retrospective chart review is provided by the IRB.
  • Verofilcon A (sphere or toric) contact lens wear as described in the protocol.
  • Best corrected spectacle distance visual acuity (VA) 20/25 or better at baseline.
  • Healthy, non-diseased eyes, as determined/known by the Investigator.

You may not qualify if:

  • Any ocular disease or condition that would contraindicate contact lens wear present at baseline.
  • Use of systemic or ocular medications that would contraindicate contact lens wear at baseline.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Scripps Optometric Group

San Diego, California, 92131, United States

Location

Pearle Vision

Jacksonville, Florida, 32246, United States

Location

Vision Health Institute

Orlando, Florida, 32803, United States

Location

Vision Salon Eye Care Associates

Blue Island, Illinois, 60406, United States

Location

Illinois College of Optometry

Chicago, Illinois, 60616, United States

Location

CORL, Indiana University

Bloomington, Indiana, 47405, United States

Location

The Eye Doctors Inc

Eden Prairie, Minnesota, 55344, United States

Location

Cornea and Contact Lens Institute of Minnesota

Edina, Minnesota, 55436, United States

Location

Complete Eye Care of Medina

Medina, Minnesota, 55340, United States

Location

Spectrum Eyecare

Jamestown, New York, 14701, United States

Location

Eyecare Professionals, Inc

Powell, Ohio, 43065, United States

Location

Optometry Group, PLLC

Memphis, Tennessee, 38111, United States

Location

MeSH Terms

Conditions

Refractive ErrorsMyopiaHyperopiaAstigmatism

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Clinical Trial Lead, VC

    Alcon Research, LLC

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2024

First Posted

June 17, 2024

Study Start

August 30, 2024

Primary Completion

March 11, 2025

Study Completion

March 11, 2025

Last Updated

July 20, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations